Compared to HFrEF, the absolute benefits on cardiovascular outcomes in HFpEF were about half the size (19 HF hospitalizations, and 5 cardiovascular deaths prevented per 1000 patient years of treatment with an SGLT-2 inhibitor). The gene discussed is SLC5A2; the disease is hydrops fetalis.